UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4169-4181

2022

Volltextzugriff (PDF)

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Clinical cancer research, 2023-11, Vol.29 (22), p.4555-4563

2023

Volltextzugriff (PDF)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

British journal of cancer, 2016-04, Vol.114 (8), p.889-896

2016

Volltextzugriff (PDF)

Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent

The New England journal of medicine, 1997-07, Vol.337 (2), p.77-82

1997

Volltextzugriff (PDF)

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3472-3479

2009

Volltextzugriff (PDF)

Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.585-585

2022

Volltextzugriff (PDF)

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer

Gynecologic oncology, 2018-05, Vol.149 (2), p.275-282

2018

Volltextzugriff (PDF)

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

Cancer chemotherapy and pharmacology, 2023-06, Vol.91 (6), p.491-499

2023

Volltextzugriff (PDF)

Abstract CT273: Evaluation of the effect of rivoceranib on the pharmacokinetics of cytochrome P450 enzyme substrates in healthy volunteers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT273-CT273

2023

Volltextzugriff (PDF)

Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing

Cancer research (Chicago, Ill.), 1995-10, Vol.55 (20), p.4531-4535

1995

Volltextzugriff (PDF)

A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.80-80

2017

Volltextzugriff (PDF)

Association of Collagen Type 1 α1 Gene Polymorphism with Bone Density in Early Childhood1

The journal of clinical endocrinology and metabolism, 1999-03, Vol.84 (3), p.853-855

1999

Volltextzugriff (PDF)

Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B187-B187

2013

Volltextzugriff (PDF)

Abstract 3752: Folate receptor expression prevalence across multiple tumor types and concordance between matched primary and metastatic tumor pairs

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3752-3752

2010

Volltextzugriff (PDF)

Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results

Blood, 2009-11, Vol.114 (22), p.3876-3876

2009

Volltextzugriff (PDF)

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program

Blood, 2007-11, Vol.110 (11), p.472-472

2007

Volltextzugriff (PDF)

Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A55-A55

2009

Volltextzugriff (PDF)

Abstract C18: Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C18-C18

2009

Volltextzugriff (PDF)

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005)

Blood, 2007-11, Vol.110 (11), p.470-470

2007

Volltextzugriff (PDF)

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015)

Blood, 2007-11, Vol.110 (11), p.2810-2810

2007

Volltextzugriff (PDF)

Prematurity and hepatoblastoma: More than just an association?

The Journal of pediatrics, 1998-10, Vol.133 (4), p.585-586

1998

Volltextzugriff (PDF)

Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC

Cancer epidemiology, biomarkers & prevention, 1997-07, Vol.6 (7), p.493-497

1997

Volltextzugriff (PDF)

Melanotic Neuroectodermal Tumor of Infancy A Case Report of Paratesticular Primary with Lymph Node Involvement

Journal of pediatric hematology/oncology, 1992, Vol.14 (4), p.356-360

1992

Volltextzugriff (PDF)

Melanotic Neuroectodermal Tumor of Infancy: A Case Report of Paratesticular Primary with Lymph Node Involvement

The Pediatric infectious disease journal, 1992-11, Vol.14 (4), p.356-360

1992

Volltextzugriff (PDF)

The magnitude and rate of decline in alpha-fetoprotein levels in children with unresectable or metastatic hepatoblastoma, predict outcome

Van Tornout, Jan Marie-Albert

1996

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(27)
Dissertationen
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

Abstract CT273: Evaluation of the effect of rivoceranib on the pharmacokinetics of cytochrome P450 enzyme substrates in healthy volunteers

Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing

A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer

Association of Collagen Type 1 α1 Gene Polymorphism with Bone Density in Early Childhood1

Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study

Abstract 3752: Folate receptor expression prevalence across multiple tumor types and concordance between matched primary and metastatic tumor pairs

Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program

Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors

Abstract C18: Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005)

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015)

Prematurity and hepatoblastoma: More than just an association?

Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC

Melanotic Neuroectodermal Tumor of Infancy A Case Report of Paratesticular Primary with Lymph Node Involvement

Melanotic Neuroectodermal Tumor of Infancy: A Case Report of Paratesticular Primary with Lymph Node Involvement

The magnitude and rate of decline in alpha-fetoprotein levels in children with unresectable or metastatic hepatoblastoma, predict outcome

Suchergebnisse filtern